Werewolf Therapeutics, Inc. - SIC # 2830 -

Ticker Exchange SIC # Website Latest Ticker
HOWL Nasdaq 2830 werewolftx.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Werewolf Therapeutics, Inc.

Oramed Pharmaceuticals And 2 Other US Penny Stocks To Watch - Feb 12th, 2025 12:11 am
Werewolf Therapeutics provides business update, highlights 2025 outlook - Jan 14th, 2025 1:35 pm
Werewolf Therapeutics Provides Business Update and Highlights 2025 Strategic Outlook - Jan 13th, 2025 1:00 pm
Werewolf Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx Healthcare Conference - Nov 20th, 2024 1:00 pm
Werewolf Therapeutics Presents Preclinical and Clinical Data at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - Nov 7th, 2024 2:02 pm
Werewolf Therapeutics Reports Third Quarter 2024 Financial Results and Provides Business Update - Nov 7th, 2024 2:00 pm
Werewolf Therapeutics Announces Promising New Development Candidate, WTX-921, a first-of-its-kind IL-10 INDUKINE™ Molecule for Inflammatory Diseases - Oct 31st, 2024 12:00 pm
Bank of America Predicts up to ~390% Surge for These 2 ‘Strong Buy’ Stocks - Oct 20th, 2024 10:04 am
Werewolf Therapeutics to Present Posters at the Society for Immunotherapy of Cancer’s (SITC) 39th Annual Meeting - Oct 4th, 2024 1:00 pm
Werewolf Therapeutics to Participate in the H.C. Wainwright 26th Annual Global Investment Conference - Sep 3rd, 2024 12:00 pm
Werewolf Therapeutics Second Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags - Aug 10th, 2024 2:04 pm
Werewolf Therapeutics, Inc. (HOWL) Reports Q2 Loss, Lags Revenue Estimates - Aug 8th, 2024 12:15 pm
Werewolf Therapeutics Reports Second Quarter 2024 Financial Results and Provides Business Update - Aug 8th, 2024 11:05 am
Werewolf Therapeutics Highlights Initial Safety and Efficacy Data from its Ongoing Phase 1 Clinical Trial Evaluating WTX-330 in Patients with Advanced or Metastatic Solid Tumors or Non-Hodgkin Lymphoma - Jun 25th, 2024 11:00 am
Werewolf Therapeutics to Present Data from Ongoing Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors - Jun 1st, 2024 1:00 pm
Werewolf Therapeutics to Participate at the Jefferies Global Healthcare Conference - May 30th, 2024 12:00 pm
Werewolf Therapeutics to Present Updated Data from Phase 1/1b Clinical Trial of WTX-124 as Monotherapy and in Combination with Pembrolizumab in Solid Tumors at 2024 ASCO Annual Meeting - May 23rd, 2024 9:00 pm
Werewolf Therapeutics Reports First Quarter 2024 Financial Results and Provides Business Update - May 3rd, 2024 11:00 am
Werewolf Therapeutics Announces WTX-124 Clinical Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting - Apr 24th, 2024 2:05 pm
Werewolf Therapeutics Presents First Preclinical Data Highlighting IL-10 INDUKINE Molecules as a Potential Therapy for Inflammatory Bowel Disease (IBD) at AAI Annual Meeting - Apr 23rd, 2024 12:00 pm